qLC-Suite
AI for Early Detection of Lung Cancer
33%
Increment in inter-reader agreement on Chest CTs
6.6%
Increased sensitivity on CTs; <1 FPs per scan
46%
Reduction in time spent per CT
0.94
AUC (CXRs) in finding potential malignancies
300k+
CXRs processed via Incidental Detection pathways; 330+ sites
8.3%
CXRs flagged with potential malignancy risk; 5.5% of these had high-risk scores
Pre-read Assistance
Adaptable AI for assisted nodule reporting
Can be deployed on cloud or on-premises
Supports scans from all major manufacturers
World’s most widely used AI for comprehensive chest X-ray reporting. Pre-read assistance in <1 min with findings across lung, heart, pleura, mediastinum, bones, & diaphragm.
qXR
AI for CXRs
90% of the missed/mislabeled CXR have been identified with a critical abnormality by qXR with zero false positives. Missed nodules were identified with sensitivity of 0.96 & specificity of 1.
Read More
6650
Patients referred for Lung Cancer based on screening 80,000+ individuals across 20 countries.
As part of the EDISON Alliance’s 1 Billion Lives Challenge, AstraZeneca along with Qure.ai will be screening 5 million patients by 2025.
Read More
qXR detected malignant nodules with a sensitivity ranging from 0.95 to 1.00 and AUC from 0.99 to 1.
Be it lung cancer screening or incidental discovery, qCT is your trusted partner in the early detection and monitoring of lung nodules. With rapid detection, precise quantification, comprehensive characterization, and detailed 3D visualization at your fingertips, qCT ensures you never miss an opportunity for early detection.
qCT
AI for Lung CTs
Needle in Haystack: Opportunistic Screening of Lung Nodules amidst COVID-19 using Deep Learning
Read More
Schedule a Demo
Explore how qLC-Suite can add value to your care cascades and get a guided walkthrough of our capabilities.
Who We Help
To explore potential partnership with Qure, contact us.
Hospitals & Imaging centers
Screening Programs
Pulmonologists
Pharma companies
